Abstract:Background Polygenic risk scores (PRS) have ushered in a new era in genetic epidemiology, offering insights into individual predispositions to a wide range of diseases. However, despite recent marked enhancements in their predictive power, there are still challenges that need to be overcome before PRS-based models can be broadly applied in the clinic, including sufficient accuracy, easy interpretability and portability across diverse populations. Methods Leveraging trans-ancestry genome-wide association study (GWAS) meta-analysis, we generated novel, diverse summary statistics for 30 medically-related traits which were used to benchmark the performance of six existing PRS algorithms using UK biobank. Observing that SBayesRC had the best overall performance but recognizing strengths in each method, we developed an ensemble PRS model using logistic regression to combine outputs from top-performing algorithms. This ensemble model was validated on the diverse eMERGE and PAGE MEC cohorts, and the performance was compared against current state-of-the-art PRS models. To enhance predictive accuracy for clinical application, we incorporated easily-accessible clinical characteristics such as age, gender, ancestry and risk factors, creating disease prediction models intended as prospective diagnostic tests, with easily interpretable positive or negative outcomes. Results Predictive performance of PRS models improved with trans-ancestry GWAS meta-analysis and was further enhanced by the ensemble model, which surpassed state-of-art PRS models. When applied to external cohorts, performance drops were minimal, indicating good calibration. After adding clinical characteristics, 12 out of 30 models surpassed 80% AUC. Further, 25 traits exceeded the diagnostic odds ratio (DOR) of 5 and 19 traits exceeded DOR of 10 for all ancestry groups, indicating high predictive value. The highest DOR in a population with a sufficient number of cases was 66.2 for Alzheimer's disease in Europeans. Our PRS model for coronary artery disease identified 55-80 times more true coronary events than rare pathogenic variant models, reinforcing its clinical potential. The polygenic component modulated the effect of high-risk rare variants, stressing the need to consider all genetic components in clinical settings. Conclusions Newly developed PRS-based disease prediction models have sufficient accuracy and portability to warrant consideration of being used in the clinic.

UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits

A systematic evaluation of the performance and properties of the UK Biobank Polygenic Risk Score (PRS) Release

Significant sparse polygenic risk scores across 813 traits in UK Biobank

Calculating Polygenic Risk Scores (PRS) in UK Biobank: A Practical Guide for Epidemiologists

Identifying and characterizing disease subpopulations that most benefit from polygenic risk scores

Breast Cancer Polygenic Risk Score Validation and Effects of Variable Imputation

Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification

PRSice-2: Polygenic Risk Score software for biobank-scale data

Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations

Taking the risk. A systematic review of ethical reasons and moral arguments in the clinical use of polygenic risk scores

Optimization of Multi-Ancestry Polygenic Risk Score Disease Prediction Models

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

Polygenic risk score portability for common diseases across genetically diverse populations

Implementing polygenic risk scores in the clinic

A perspective on genetic and polygenic risk scores—advances and limitations and overview of associated tools

Polygenic risk scores: from research tools to clinical instruments

Methodologies underpinning polygenic risk scores estimation: a comprehensive overview

Current State and Future of Polygenic Risk Scores in Cardiometabolic Disease: A Scoping Review

Integration of Rare Large-Effect Expression Variants Improves Polygenic Risk Prediction

Calibration of polygenic risk scores is required prior to clinical implementation: results of three common cancers in UKB

Polygenic risk score comparator ( PRScomp ): Test population vs. worldwide populations